RSNA opens a window for one week where companies can showcase the latest technologies ahead of regulatory approval. Fujifilm seized this opportunity to introduce the leading edge in tomosynthesis, the Amulet Innovality that it has launched in Europe, and that once given the green light by the FDA will come to America under the name Aspire Cristalle.
In May, 2013, the U.S. Food and Drug Administration (FDA) finally took the training wheels off tomosynthesis by approving the use of Hologic's new C-View 2D imaging in place of conventional 2D mammograms previously required as part of a breast tomosynthesis screening exam.
Research using an analytical health economics model has suggested the current system of screening within the UK’s National Health Service (NHS) is only moderately likely to be cost effective.
With the help of a commercially available CAD (computer-assisted diagnosis) programme, MRI can provide prognostic data on the development of distant metastases in the further course of breast cancer.
Dr. Paula Martínez Miravete didn’t set out to change breast imaging in Spain when she first adopted breast tomosynthesis.
The movement for interoperability among health information devices and systems has spread across Europe reaching Turkey, which will be host to the European IHE Connectathon in Istanbul this April
New business ventures, new systems – and those include 3-D mammography
With 350,000 mammography screenings annually, Unilabs Sweden finds itself on the leading edge for research in mammography and pioneering patient education programmes. John Brosky reports
A first in medical imaging is still unknown for Kit Vaughan, who is ready to simultaneously scan with X-rays and ultrasound for breast screening. Stay tuned for the results at RSNA 2013, says EH Correspondent John Brosky
Study suggests a new method to measure breast density can help determine cancer risk
Much, if not even everything, may have been said already about the multimodal approach in breast diagnostics. However, Professor Rüdiger Schulz-Wendtland at the Institute of Radiology, University Hospital Erlangen, says there is still surprising news from this field – innovations in multimodal breast diagnostics, for example.
Germany’s mammography screening programme, introduced in 2005, was rolled out across the country in 2009 for women between the ages of 50 and 69 years. The mammo screening coordination office, which heads up and monitors the country’s 94 screening units, has published for the first time an evaluation report with follow-up examinations after a twoyear period.
Magnetic resonance imaging is a long-established, highquality and safe examination tool. Why, therefore, do German gynaecologists and radiologists question its value in breast cancer diagnoses? Indeed the question ‘Breast MRI - yes or no?’ has split the medical community. One ardent champion of breast MRI is Professor Christiane Kuhl MD, director of the diagnostic and interventional radiology…
Breast cancer screening for women between 40 and 49 years – yes or no? This is one of the most controversial issues as this year’s European Congress of Radiology (ECR) in Vienna. For Professor Dr Andy Evans of the Centre for Oncology & Molecular Medicine at the University of Dundee the answer is clear: “Yes. There is good evidence that breast cancer screening for women in their 40s is…
A multi-disciplinary team approach is crucial if healthcare professionals are to offer breast cancer patients the best possible care in the years ahead. That was the opinion voiced by three experts at an ECR 2012 session on Saturday afternoon with delegates addressed by a radiologist, surgeon and an oncologist.
Early this year the radiology and nuclear medicine practice of Doctors Andreas Blynow, Frank Muller, Jorg Kowalski in Ludwigshafen, Germany, began to offer breast examinations using Europe’s first Positron Emission Mammography (PEM) scanner. With 15 years experience with Positron Emission Tomography (PET), Dr Muller introduced the new PEM scanner to the partners’ practice to detect and assess…
Hologic a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, will launch four ready-to-market technologies at the European Congress of Radiology.
MRI: Although an area of constant debate, this is becoming a widely accepted clinical modality in Europe. However, researchers in The Netherlands have shown that performing pre-operative breast MRI in all women with invasive lobular carcinoma (ILC) can reduce the need for re-excision.
In Europe, 350,000 women are diagnosed with breast cancer annually. About 90% of them can be cured if the cancer is detected at a very early stage. To improve early detection almost all European countries have gradually initiated regional screening programmes, even though the benefits are discussed controversially from time to time.
iSOFT Radiology reporting has been upgraded with complementary and double mammography reporting. This upgrade is available to iSOFT RIS users with immediate effect. The new workplace profile contains reports for correction and release, as well as the examinations to be appraised.
Two years ago Dr Michael Michell and team at King’s College Hospital, London, set out to explore the benefits of tomosynthesis over conventional 2-D mammography. Their study has shown advantages in diagnostic accuracy and indicates that tomosynthesis could help to reduce the number of patient recalls for further examination and thus anxiety among women.
‘As we become more successful in the early detection and treatment of breast cancer, we tend to trivialise it. Yet one in 9 women still get breast cancer. Half of them become depressed, their partners don’t know how to react and their families are in disarray. We need to stop trivialising breast cancer. It kills women.’ So says Dr Fabienne Liebens, Head of the Saint-Pierre Hospital’s…
Expert warns that breast screening across the country needs to undergo a dramatic transformation over the next 15 years, Mark Nicholls reports.
The daily management of around 700 examinations within the national mammography screening programme keeps Dr Ilse Vejborg and her team at Rigshospitalet pretty busy. ‘We have the largest screening unit in Denmark with 200,000 women aged 50-69 years in the target group invited for an examination every second year,’ she explains.
Films with vivid 3-D images draw millions to cinemas – regardless of the plot. This technology, which is based on a stereoscopic effect, is not only entertaining but also medically relevant, as demonstrated by the Amulet three-dimensional digital mammography system produced by Fujifilm.
